在高度活跃的复发性复发性硬化症患者中,真实世界对皮下纳塔利祖马布的评估
Tarunya Arun1, Sarmad Al-Araji2, Eleanor Pye2
1University Hospitals of Coventry and Warwickshire, Neuroscience, Coventry, UK; Warwick Medical School, University of Warwick, Coventry, UK.
Multiple sclerosis and related disorders
|November 19, 2025
概括
皮下纳塔利祖马布是一种安全有效的高活性复发性复发性多发性硬化症 (RRMS) 的治疗方法,其疗效与静脉注射途径相当. 这项实践研究证实了其在预防复发和残疾进展方面的好处.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 纳塔利祖马布是高度活跃的复发性复发性多发性硬化症 (RRMS) 的关键疗法.
- 静脉注射 (IV) 是传统的,但皮下注射 (SC) natalizumab提供了方便.
- 有限的现实世界数据存在,比较SC与IV natalizumab疗效.
研究的目的:
- 评估在高度活跃的RRMS患者中SC natalizumab的实际结果.
- 为了比较SC纳塔利祖马布的疗效和安全性与IV给药.
- 为了评估 SC natalizumab 的临床和放射性稳定性.
主要方法:
- 对63名接受SC纳塔利祖马布 (300毫克) 的患者进行了回顾性观察队列研究.
- 对临床结果的分析:年均复发率 (ARR),扩大残疾状态量表 (EDSS) 和MRI损伤活动.
- 至少12个月的随访持续时间,以评估疗效.
主要成果:
- 55名患者的平均ARR为0.03,随访时间≥12个月.
- 在12个月后,有94%的无复发和85%的稳定/改善EDSS.
- 没有观察到新的MRI病变;在以前未接受治疗的患者和切换患者之间,疗效相似.
结论:
- 在高度活跃的RRMS中,SC natalizumab是非常有效和安全的.
- 现实世界的数据支持SC natalizumab作为IV给药的可行替代品.
- 观察到的临床和放射性稳定性与关键试验发现一致.
相关概念视频
Bioavailability Study Design: Healthy Subjects Versus Patients
136
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
136
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
239
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
239
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
224
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
224
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
465
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
465
Nephrotic Syndrome II : Assessment and Medical Management
184
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
184
Bioavailability Study Design: Single Versus Multiple Dose Studies
189
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
189


